盐酸埃克替尼治疗晚期非小细胞肺癌 196例临床观察

目的]观察盐酸埃克替尼治疗晚期非小细胞肺癌（NSCLC）的疗效及安全性。方法]196例晚期NSCLC患者使用盐酸埃克替尼,直到病变进展或出现不可耐受的不良反应,观察治疗疗效及安全性。结果]可评价疗效196例,CR 3例（1.5%）,PR 57例（29.1%）,SD 78例（39.8%）,PD 58例（29.5%）。总有效率为30.6%（60/196）,疾病控制率为70.4%（138/196）,中位无进展生存期（PFS）为6.5个月,中位生存时间（MST）为14.2个月,1年生存率为60.7%。腺癌患者有效率、疾病控制率及中位PFS显著高于非腺癌患者（P〈0.05）。最常见的不良反应为Ⅰ~Ⅱ度的皮疹（62例,31.6%）及腹泻（32例,16.3%）。结论]盐酸埃克替尼治疗晚期非小细胞肺癌安全、有效,不良反应可耐受。

Clinical Observation of Icotinib in the Treatment for 196 Cases with Advanced Non-small Cell Lung Cancer

Purpose] To investigate the efficacy and safety of icotinib in the treatment for ad- vanced non-small cell lung cancer （NSCLC）. Methods] A total of 196 cases of NSCLC patients received icotinib continuously until disease progression or developing unacceptable toxicity. And the efficacy and safety of icotinib for the advanced NSCLC patients were analyzed. Results] The efficacy of all the 196 NSCLC patients were evaluated. Three cases （1.5%） achieved complete response（CR）,57 cases（29.1%） achieved partial response（PR）,78 cases（39.8%） achieved stable disease（SD）, and 58 cases （29.5%） exhibited progress disease（PD）. The overall response rate（RR） and the disease control rate （DCR） of icotinib were 30.6%（60/196） and 70.4%（138/196） respectively, with median progression-free survival（mPFS）,median survival time （MST） and 1-year survival rate 6.5 months,14.2 months,and 60.7% ,respectively. The RR,DCR and mPFS were significantly higher in adenocarcinoma patients than those in non-adenocarcinoma patients （P〈0.05）. The com- mon toxicities were rash （62 cases,31.6%） and diarrhea （32 cases, 16.3%） with grade Ⅰ to Ⅱ. Conclusion] Icotinib is effective and safe in the treatment for advanced NSCLC patients with tol- erable toxitity.